Teva API
TAPI is the API manufacturing and CDMO arm of Teva Pharmaceutical Industries, supplying 350+ active pharmaceutical ingredients and custom development services across peptides, oligonucleotides, small molecules, and biosynthetic modalities to global pharmaceutical manufacturers. Founded in 1935 with 1,001–5,000 employees.
- Company typePrivate
- Founded1935
- HeadquartersWoodcliff Lake, United States
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Teva API does
TAPI (legal entity Assia Chemical Industries Ltd), the API manufacturing and CDMO arm of Teva Pharmaceutical Industries, manufactures and supplies over 350 active pharmaceutical ingredients and offers custom development and manufacturing services across multiple modalities including small molecules, peptides, oligonucleotides, fermentation products, steroids, and high potents/ADC. Founded in 1935 and headquartered in Woodcliff Lake, NJ with the legal entity domiciled in Israel, the company employs between 1,001 and 5,000 people and operates as the leading international supplier of APIs to generic drug manufacturers globally.
The company's technology base spans 85+ years of manufacturing expertise, supported by DoE-driven process optimization, PAT-enabled quality control, and specialized containment for high-potency compounds. Core offerings include the API Catalog (350+ off-the-shelf generic APIs), CDMO Services (custom development from concept to commercial scale), and a dedicated peptides and oligonucleotides practice with GLP-1 manufacturing capability. The TAPI Connect self-service portal provides customers 24/7 access to documentation, order tracking, and regulatory updates. Recent strategic moves include a biosynthetic ingredient partnership with Antheia (November 2025) and a global licensing agreement with Sagimet Biosciences for Resmetirom API (December 2025).
TAPI generates revenue through three streams: API product sales, CDMO services under multi-year contracts with development and manufacturing fees, and licensing/royalty arrangements. Pricing is quote-based and not publicly disclosed. The company sells primarily to pharmaceutical manufacturers through direct enterprise field sales, the TAPI Connect self-service portal, and presence at major industry events including CPHI, TIDES, and OPRD conferences. Its customer base spans generic drug manufacturers, innovator pharmaceutical companies, and emerging biotechs requiring specialized peptide or biosynthetic API development.
Teva API firmographics
Firmographics- Name
- Teva API
- Legal name
- Assia Chemical Industries Ltd
- Website
- https://teva-api.com
- Company type
- Private
- Founded year
- 1935
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- TAPI is the API manufacturing and CDMO arm of Teva Pharmaceutical Industries, supplying 350+ active pharmaceutical ingredients and custom development services across peptides, oligonucleotides, small molecules, and biosynthetic modalities to global pharmaceutical manufacturers. Founded in 1935 with 1,001–5,000 employees.
- Ownership category
- akta.pro rank
Teva API industry classification
Industry- Product category
- Active Pharmaceutical Ingredients (API) Manufacturing
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), Pharmaceutical and Medicine Manufacturing (32541)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Drug Substance–Drug Product Integrated CDMO (HLAGABAG)
- akta.pro secondary industries
- Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule API Commercial Manufacturing (HLAGAHAB), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM)
Keywords
Where Teva API is headquartered
LocationHeadquarters
- HQ city
- Woodcliff Lake
- HQ country
- United States
- HQ region
- North America
Markets served
Teva API business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Personnel, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- API Manufacturing and Sales: TAPI manufactures and supplies active pharmaceutical ingredients from its portfolio of 350+ products, serving as the leading international supplier of APIs for generic drug manufacturers worldwide
- CDMO Services: Custom development and manufacturing organization services offering tailored solutions across modalities including peptides, oligonucleotides, fermentation products, steroids, small molecules, and high potents/ADC. Revenue generated through development fees, manufacturing fees, and long-term supply agreements
- Licensing and Partnership Agreements: Strategic licensing arrangements such as the global license agreement with Sagimet Biosciences for innovative forms of Resmetirom API
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Quote-based pricing for API products and CDMO services |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels5 records
Teva API product offering
Product offeringCore offering
TAPI manufactures and supplies active pharmaceutical ingredients (APIs) from a portfolio of over 350 products, serving as the leading international supplier of APIs for generic drug manufacturers worldwide. In addition, TAPI provides custom Contract Development and Manufacturing Organization (CDMO) services across multiple modalities including peptides, oligonucleotides, fermentation products, steroids, small molecules, and high potents/ADC. The company is supported by the TAPI Connect self-service customer portal for document access and order management.
Product overview
TAPI (Technology API Services) is a pharmaceutical Active Pharmaceutical Ingredient (API) manufacturer offering a unified portfolio of over 350 API products combined with CDMO (Contract Development and Manufacturing Organization) services. The core offering consists of the API Catalog for off-the-shelf generic APIs, CDMO Services for custom development and manufacturing, and Peptides & Oligonucleotides for specialized development. TAPI Connect provides the customer-facing digital portal for document access and order management. Founded in 1935, the company leverages 85+ years of manufacturing expertise to serve the global pharmaceutical industry.
Differentiator
Problem solved
Functional benefit
Products and services
- API Catalog
Quantifiable outcome
- 350+ products in portfolio
- +1 more outcomes
Companies that use Teva API
Customer profileSegments4 records
Ideal customer profiles3 records
Teva API technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature4 records
Teva API partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Sagimet BiosciencescoreTAPI and Sagimet Biosciences announced a global license agreement for innovative forms of Resmetirom API for Sagimet's fixed dose combination program. TAPI provides licensing for specific API forms supporting Sagimet's pharmaceutical development.
- AntheiacoreTAPI and Antheia announced a strategic partnership to advance commercialization of biosynthetic pharmaceutical ingredients. This collaboration combines Antheia's biosynthetic technology capabilities with TAPI's manufacturing expertise and global supply chain to bring innovative biosynthetic APIs to market.
Scale indicators3 records
Recent moves5 records
Expansion highlights6 records
Teva API competitors and assessment
Company assessmentMarket position
Competitive moat5 records
Key risks5 records
Key highlights7 records
Customer concentration
Teva API social profiles
Digital presenceTeva API financial estimates
Financial estimateRevenue estimate
Valuation estimate
Teva API leadership team
Management profileNumber of profiles
Profiles1 record
Teva API funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Teva API M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Teva API
What does Teva API do?
TAPI manufactures and supplies active pharmaceutical ingredients (APIs) from a portfolio of over 350 products, serving as the leading international supplier of APIs for generic drug manufacturers worldwide. In addition, TAPI provides custom Contract Development and Manufacturing Organization (CDMO) services across multiple modalities including peptides, oligonucleotides, fermentation products, steroids, small molecules, and high potents/ADC. The company is supported by the TAPI Connect self-service customer portal for document access and order management.
Is Teva API a public or private company?
Teva API is a private company. It is classified as corporate owned and is currently operating.
When was Teva API founded?
Teva API was founded in 1935. It employs 1,001 to 5,000 people.
Where is Teva API based?
Teva API is headquartered in Woodcliff Lake, United States, in the North America region.
How does Teva API make money?
Three revenue lines are on record. API Manufacturing and Sales are the primary driver. The others are CDMO Services and licensing and Partnership Agreements.
Does Teva API have an API?
No public API is recorded for Teva API.
What industry is Teva API in?
Teva API's product category is Active Pharmaceutical Ingredients (API) Manufacturing. Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 3254 and its SIC code is 8731.